国际妇产科学杂志

国际妇产科学杂志 ›› 2017, Vol. 44 ›› Issue (2): 237-240.

• 论著 • 上一篇    

二甲双胍联合罗氟司特治疗多囊卵巢综合征的临床观察

姚超，陈艳，全燕   

  1. 442000  湖北省十堰市妇幼保健院妇产科
  • 收稿日期:2016-05-11 修回日期:2017-02-16 出版日期:2017-04-15 发布日期:2017-05-18
  • 通讯作者: 全燕，E-mail：1592224842@qq.com E-mail:114528069@qq.com

Effect of the Combination of Metformin and Roflumilast in Patients with Polycystic Ovary Syndrome

YAO Chao，CHEN Yan，QUAN Yan   

  1. Department of Obstetrics and Gynecology，Maternal and Child Health Hospital of Shiyan，Shiyan 442000，Hubei Province，China
  • Received:2016-05-11 Revised:2017-02-16 Published:2017-04-15 Online:2017-05-18
  • Contact: QUAN Yan，E-mail：1592224842@qq.com E-mail:114528069@qq.com

PDF (PC)

6676

被引次数

2

摘要：  目的：探究二甲双胍联合罗氟司特治疗多囊卵巢综合征（PCOS）的临床疗效。方法：选择2013年6月—2015年6月我院妇产科收治的53例肥胖型PCOS患者，按照患者先后治疗顺序将其分为对照组（仅给予二甲双胍治疗，前25例患者）和观察组（给予二甲双胍联合罗氟司特治疗，后28例患者）。2组患者均治疗3个月，测量治疗前后体质量、体质量指数（BMI）、腰围、血糖、胰岛素、胰岛素抵抗指数（HOMA-IR）、黄体生成激素、卵泡刺激素、雄烯二酮、总睾酮和游离睾酮。结果：2组患者在经过3个月的治疗后，观察组患者的体质量、BMI和腰围较治疗前显著下降（P＜0.05），且观察组与对照组比较差异有统计学意义（P＜0.001）；观察组和对照组的血糖、HOMA-IR比较差异有统计学意义（P＜0.05）。此外，游离睾酮和雄烯二酮水平在组内治疗前后比较以及2组之间比较，差异均有统计学意义（P＜0.05）；2组患者治疗前血脂功能指标比较，差异均无统计学意义（P＞0.05）；治疗后观察组总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL-C）以及低密度脂蛋白胆固醇（LDL-C）水平均较对照组改善，差异有统计学意义（P＜0.05）。结论：采用罗氟司特联合二甲双胍进一步减轻肥胖型PCOS患者的体质量，为PCOS的治疗提供了一个新的方案。
   

关键词: 二甲双胍, 磷酸二酯酶抑制剂, 多囊卵巢综合征, 治疗

Abstract: Objective: To evaluate the combination of metformin and roflumilast in patients with polycystic ovary syndrome (PCOS). Methods：A total of 53 obese women with PCOS from June 2013 to June 2015 were investigated in this study. They were randomized to divide into control group （treatment with metformin, the initial 25 cases） and observed group (ｔreatment with metformin and roflumilast, followed by 28 cases）. Each group has been treated for three months. The weight, BMI, waist circumference, glucose, insulin, HOMA-IR, luteinizing hormone, follicle-stimulating hormone, androstenedione, and total and free testosterone were calculated before and after treatment. Results：After treatment with 3 months, the weight, BMI and waist circumference in observed group were significantly decreased （P＜0.05）, and there were significantly difference between two groups （P＜0.001）. Besides, the glucose and HOMA-IR were significantly difference between treatment groups （P＜0.05）. In addition, statistically significant within- and between-treatment differences were found in free testosterone and androstenedione （P＜0.05）. No difference was observed in serum total cholesterol （ＴＣ）, triglycerides （TG）, high-density lipoprotein-cholesterol （HDL-C） and  low-density lipoprotein-cholesterol （LDL-C） before treatment, however there was significantly difference between two groups after treatment （P＜0.05）. Conclusions：Combined treatment with roflumilast and metformin could reduce body weight in obese women with PCOS, and it encourage further exploration of the use of this drug for PCOS.

Key words:  , Metformin, Phosphodiesterase inhibitors, Polycystic ovary syndrome, Therapy